NASDAQ:TECH - BIO-TECHNE Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $151.55 -1.56 (-1.02 %) (As of 07/16/2018 04:00 PM ET)Previous Close$153.11Today's Range$151.24 - $152.9652-Week Range$112.33 - $166.81Volume95,002 shsAverage Volume210,093 shsMarket Capitalization$5.75 billionP/E Ratio44.31Dividend Yield0.84%Beta0.73 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Receive TECH News and Ratings via Email Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical SymbolNASDAQ:TECH CUSIP87837710 Webwww.techne-corp.com Phone612-379-8854 Debt Debt-to-Equity Ratio0.37 Current Ratio5.55 Quick Ratio4.30 Price-To-Earnings Trailing P/E Ratio44.31 Forward P/E Ratio37.42 P/E Growth2.25 Sales & Book Value Annual Sales$563 million Price / Sales10.11 Cash Flow$4.9951 per share Price / Cash30.34 Book Value$25.44 per share Price / Book5.96 Profitability EPS (Most Recent Fiscal Year)$3.42 Net Income$76.08 million Net Margins18.29% Return on Equity14.75% Return on Assets9.35% Miscellaneous Employees1,800 Outstanding Shares37,570,000Market Cap$5,752.96 BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions What is BIO-TECHNE's stock symbol? BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH." How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE? BIO-TECHNE declared a quarterly dividend on Thursday, May 3rd. Stockholders of record on Monday, May 14th will be given a dividend of $0.32 per share on Friday, May 25th. This represents a $1.28 annualized dividend and a dividend yield of 0.84%. The ex-dividend date of this dividend is Friday, May 11th. View BIO-TECHNE's Dividend History. How were BIO-TECHNE's earnings last quarter? BIO-TECHNE Corp (NASDAQ:TECH) released its earnings results on Wednesday, May, 2nd. The biotechnology company reported $1.21 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.07. The biotechnology company had revenue of $164 million for the quarter, compared to the consensus estimate of $163.43 million. BIO-TECHNE had a return on equity of 14.75% and a net margin of 18.29%. The company's quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.97 earnings per share. View BIO-TECHNE's Earnings History. When is BIO-TECHNE's next earnings date? BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for BIO-TECHNE. What price target have analysts set for TECH? 6 Wall Street analysts have issued 12-month price targets for BIO-TECHNE's stock. Their predictions range from $115.00 to $185.00. On average, they anticipate BIO-TECHNE's stock price to reach $157.00 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Ratings for BIO-TECHNE. What is the consensus analysts' recommendation for BIO-TECHNE? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of BIO-TECHNE's key competitors? Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA). Who are BIO-TECHNE's key executives? BIO-TECHNE's management team includes the folowing people: Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52) Has BIO-TECHNE been receiving favorable news coverage? Headlines about TECH stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BIO-TECHNE earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are BIO-TECHNE's major shareholders? BIO-TECHNE's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.37%), Confluence Investment Management LLC (0.08%), First National Bank of Omaha (0.07%), Bank of Montreal Can (0.05%), State of Alaska Department of Revenue (0.03%) and Affiance Financial LLC (0.03%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE. Which institutional investors are selling BIO-TECHNE stock? TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, First National Bank of Omaha, Bremer Trust National Association, State of Alaska Department of Revenue and Confluence Investment Management LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE. Which institutional investors are buying BIO-TECHNE stock? TECH stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Affiance Financial LLC, Wendell David Associates Inc. and Contravisory Investment Management Inc.. View Insider Buying and Selling for BIO-TECHNE. How do I buy shares of BIO-TECHNE? Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BIO-TECHNE's stock price today? One share of TECH stock can currently be purchased for approximately $151.55. How big of a company is BIO-TECHNE? BIO-TECHNE has a market capitalization of $5.75 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. BIO-TECHNE employs 1,800 workers across the globe. How can I contact BIO-TECHNE? BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected] MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 197 (Vote Outperform)Underperform Votes: 222 (Vote Underperform)Total Votes: 419MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?